Drug Trial Radar · NCT00622908
Clinical and Microbial Efficacy of ISV403 in Bacterial Conjunctivitis
Last checked: Nov 20, 2026Latest source record: Mar 24, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
270
Actual
Start
Dec 2004
Primary completion
Jun 2005
Study completion Jun 2005
Sponsor
- Lead sponsor
- Bausch & Lomb IncorporatedIndustry
- Sponsor type
- Industry
- First posted
- Feb 25, 2008
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 1 year
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the clinical and microbial efficacy of ISV-403 administered three times a day (TID) for 5 days compared to vehicle three times a day for 5 days in the treatment of bacterial conjunctivitis
Conditions
- Bacterial Conjunctivitis
Interventions
ISV-403Drug
0.6% TID, 5 days
VehicleDrug
Vehicle of ISV-403 TID, 5 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical Resolution of Baseline Bacterial Conjunctivitis (Day 8 or 9)Time frame: Visit 3 - day 8 or 9
- Eradication of Baseline Pathogens (Day 8 or 9)Time frame: Visit 3 - Day 8 or day 9
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.